Dr. Reddy’s Laboratories files patent for 6-substituted pyridazine compounds for treating diseases dependent on SMARCA2/SMARCA4

Discover how Dr. Reddy's patent for innovative pyridazine compounds offers promising treatments for diseases dependent on SMARCA2 and SMARCA4 proteins, including various cancers. Explore detailed chemical structures and potential therapeutic benefits.

Related Posts

Diffusion Pharma’s stockholders support merger with EIP...

Aug 16, 2023

Astellas Pharma gets grant for novel carbocyclic prolin...

May 3, 2024

Opinion: What does it mean to be ‘in recovery’? We need...

Jul 12, 2023